Suppr超能文献

肺动脉高压中的钾通道。

Potassium channels in pulmonary arterial hypertension.

机构信息

Pulmonary Hypertension Research Group, Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Québec, QC, Canada

Pulmonary Hypertension Research Group, Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Québec, QC, Canada.

出版信息

Eur Respir J. 2015 Oct;46(4):1167-77. doi: 10.1183/13993003.00798-2015. Epub 2015 Sep 4.

Abstract

Pulmonary arterial hypertension (PAH) is a devastating cardiopulmonary disorder with various origins. All forms of PAH share a common pulmonary arteriopathy characterised by vasoconstriction, remodelling of the pre-capillary pulmonary vessel wall, and in situ thrombosis. Although the pathogenesis of PAH is recognised as a complex and multifactorial process, there is growing evidence that potassium channels dysfunction in pulmonary artery smooth muscle cells is a hallmark of PAH. Besides regulating many physiological functions, reduced potassium channels expression and/or activity have significant effects on PAH establishment and progression. This review describes the molecular mechanisms and physiological consequences of potassium channel modulation. Special emphasis is placed on KCNA5 (Kv1.5) and KCNK3 (TASK1), which are considered to play a central role in determining pulmonary vascular tone and may represent attractive therapeutic targets in the treatment of PAH.

摘要

肺动脉高压(PAH)是一种具有多种病因的破坏性心肺疾病。所有形式的 PAH 都具有共同的肺小动脉病变特征,包括血管收缩、毛细血管前肺血管壁重塑和原位血栓形成。尽管 PAH 的发病机制被认为是一个复杂的多因素过程,但越来越多的证据表明,肺动脉平滑肌细胞中的钾通道功能障碍是 PAH 的标志。除了调节许多生理功能外,钾通道表达和/或活性的降低对 PAH 的发生和进展有显著影响。本综述描述了钾通道调节的分子机制和生理后果。特别强调了 KCNA5(Kv1.5)和 KCNK3(TASK1),它们被认为在决定肺血管张力方面发挥着核心作用,可能成为治疗 PAH 的有吸引力的治疗靶点。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验